Tumor tissue recycling - A new combination treatment for solid tumors

Experimental and preliminarily clinical research

Biaoru Li, Jianqing Ding, Alan Larson, Shiwen Song

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Although H and H combination treatment (high active TIL and high sensitive drugs) as previously described to solid tumor patients is more efficient than single-agent treatments such as TIL adoptive immunotherapy, it has a short-term efficiency for the immune response to metastatic cancers. Currently, a new version of the combination of active and adoptive immune response was established: TILs, tumor vaccines and high sensitive drugs. The experimental results demonstrated that TILs from 49 cases (65) were more than 1000 expansion-fold and only 6 cases (24) less than 500 fold. The peaks of TIL 3H-TdR cytotoxicity test from 35 of 64 TTL specimens were kept from 40 to 56 days. TIL phenotypes studied here indicated CD3 80 21 CD4 37 ± 21, CD8 44 18 and HLA DR69 24 after IL2 induction, in contrast, to CD3 20 12 CD4 10 7, CD8 11 3 and HLA DR 30 16 before induction. Thirty two of 75 cases were assayed using the chemosensitivity test. The distribution of positive rates for the chemosensitivity test were slightly different in different tumors regarding tissues in liver, lung, ovary, breast, and melanoma, 2 cases with melanoma all showed negative results. The results of tumor vaccine using TNF-alpha gene transduction demonstrated that the expression of HLA Class I and HLA Class II were dramatically increased 87 and 43. After implanting tumor cells via transduced TNF-alpha retroviral vector into 6-12 week old BALB/c nude mice, only one subject of nine nude mice had a tumor weight of 2.67 g, but the control group all displayed tumors with a weight of 3.24 0.56 g. Preliminarily clinical trials also showed that the new version was obviously a promising combination.

Original languageEnglish (US)
Pages (from-to)433-438
Number of pages6
JournalIn Vivo
Volume13
Issue number5
StatePublished - Sep 1 1999
Externally publishedYes

Fingerprint

Recycling
Tumors
Tissue
Research
Cancer Vaccines
Neoplasms
Nude Mice
Melanoma
Tumor Necrosis Factor-alpha
Active Immunity
Adoptive Immunotherapy
Therapeutics
Transistor transistor logic circuits
HLA-DR Antigens
Cytotoxicity
Tumor Burden
Pharmaceutical Preparations
Liver
Interleukin-2
Ovary

Keywords

  • Chemosensitivity test
  • Gene therapy
  • Tumor
  • Tumor infiltrating lymphocytes (TILs)
  • Vaccine

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Cite this

Tumor tissue recycling - A new combination treatment for solid tumors : Experimental and preliminarily clinical research. / Li, Biaoru; Ding, Jianqing; Larson, Alan; Song, Shiwen.

In: In Vivo, Vol. 13, No. 5, 01.09.1999, p. 433-438.

Research output: Contribution to journalArticle

Li, Biaoru ; Ding, Jianqing ; Larson, Alan ; Song, Shiwen. / Tumor tissue recycling - A new combination treatment for solid tumors : Experimental and preliminarily clinical research. In: In Vivo. 1999 ; Vol. 13, No. 5. pp. 433-438.
@article{f3c65e8d97144a7dbb6d19bd22d7e421,
title = "Tumor tissue recycling - A new combination treatment for solid tumors: Experimental and preliminarily clinical research",
abstract = "Although H and H combination treatment (high active TIL and high sensitive drugs) as previously described to solid tumor patients is more efficient than single-agent treatments such as TIL adoptive immunotherapy, it has a short-term efficiency for the immune response to metastatic cancers. Currently, a new version of the combination of active and adoptive immune response was established: TILs, tumor vaccines and high sensitive drugs. The experimental results demonstrated that TILs from 49 cases (65) were more than 1000 expansion-fold and only 6 cases (24) less than 500 fold. The peaks of TIL 3H-TdR cytotoxicity test from 35 of 64 TTL specimens were kept from 40 to 56 days. TIL phenotypes studied here indicated CD3 80 21 CD4 37 ± 21, CD8 44 18 and HLA DR69 24 after IL2 induction, in contrast, to CD3 20 12 CD4 10 7, CD8 11 3 and HLA DR 30 16 before induction. Thirty two of 75 cases were assayed using the chemosensitivity test. The distribution of positive rates for the chemosensitivity test were slightly different in different tumors regarding tissues in liver, lung, ovary, breast, and melanoma, 2 cases with melanoma all showed negative results. The results of tumor vaccine using TNF-alpha gene transduction demonstrated that the expression of HLA Class I and HLA Class II were dramatically increased 87 and 43. After implanting tumor cells via transduced TNF-alpha retroviral vector into 6-12 week old BALB/c nude mice, only one subject of nine nude mice had a tumor weight of 2.67 g, but the control group all displayed tumors with a weight of 3.24 0.56 g. Preliminarily clinical trials also showed that the new version was obviously a promising combination.",
keywords = "Chemosensitivity test, Gene therapy, Tumor, Tumor infiltrating lymphocytes (TILs), Vaccine",
author = "Biaoru Li and Jianqing Ding and Alan Larson and Shiwen Song",
year = "1999",
month = "9",
day = "1",
language = "English (US)",
volume = "13",
pages = "433--438",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Tumor tissue recycling - A new combination treatment for solid tumors

T2 - Experimental and preliminarily clinical research

AU - Li, Biaoru

AU - Ding, Jianqing

AU - Larson, Alan

AU - Song, Shiwen

PY - 1999/9/1

Y1 - 1999/9/1

N2 - Although H and H combination treatment (high active TIL and high sensitive drugs) as previously described to solid tumor patients is more efficient than single-agent treatments such as TIL adoptive immunotherapy, it has a short-term efficiency for the immune response to metastatic cancers. Currently, a new version of the combination of active and adoptive immune response was established: TILs, tumor vaccines and high sensitive drugs. The experimental results demonstrated that TILs from 49 cases (65) were more than 1000 expansion-fold and only 6 cases (24) less than 500 fold. The peaks of TIL 3H-TdR cytotoxicity test from 35 of 64 TTL specimens were kept from 40 to 56 days. TIL phenotypes studied here indicated CD3 80 21 CD4 37 ± 21, CD8 44 18 and HLA DR69 24 after IL2 induction, in contrast, to CD3 20 12 CD4 10 7, CD8 11 3 and HLA DR 30 16 before induction. Thirty two of 75 cases were assayed using the chemosensitivity test. The distribution of positive rates for the chemosensitivity test were slightly different in different tumors regarding tissues in liver, lung, ovary, breast, and melanoma, 2 cases with melanoma all showed negative results. The results of tumor vaccine using TNF-alpha gene transduction demonstrated that the expression of HLA Class I and HLA Class II were dramatically increased 87 and 43. After implanting tumor cells via transduced TNF-alpha retroviral vector into 6-12 week old BALB/c nude mice, only one subject of nine nude mice had a tumor weight of 2.67 g, but the control group all displayed tumors with a weight of 3.24 0.56 g. Preliminarily clinical trials also showed that the new version was obviously a promising combination.

AB - Although H and H combination treatment (high active TIL and high sensitive drugs) as previously described to solid tumor patients is more efficient than single-agent treatments such as TIL adoptive immunotherapy, it has a short-term efficiency for the immune response to metastatic cancers. Currently, a new version of the combination of active and adoptive immune response was established: TILs, tumor vaccines and high sensitive drugs. The experimental results demonstrated that TILs from 49 cases (65) were more than 1000 expansion-fold and only 6 cases (24) less than 500 fold. The peaks of TIL 3H-TdR cytotoxicity test from 35 of 64 TTL specimens were kept from 40 to 56 days. TIL phenotypes studied here indicated CD3 80 21 CD4 37 ± 21, CD8 44 18 and HLA DR69 24 after IL2 induction, in contrast, to CD3 20 12 CD4 10 7, CD8 11 3 and HLA DR 30 16 before induction. Thirty two of 75 cases were assayed using the chemosensitivity test. The distribution of positive rates for the chemosensitivity test were slightly different in different tumors regarding tissues in liver, lung, ovary, breast, and melanoma, 2 cases with melanoma all showed negative results. The results of tumor vaccine using TNF-alpha gene transduction demonstrated that the expression of HLA Class I and HLA Class II were dramatically increased 87 and 43. After implanting tumor cells via transduced TNF-alpha retroviral vector into 6-12 week old BALB/c nude mice, only one subject of nine nude mice had a tumor weight of 2.67 g, but the control group all displayed tumors with a weight of 3.24 0.56 g. Preliminarily clinical trials also showed that the new version was obviously a promising combination.

KW - Chemosensitivity test

KW - Gene therapy

KW - Tumor

KW - Tumor infiltrating lymphocytes (TILs)

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0033401386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033401386&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 433

EP - 438

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 5

ER -